Authors

Latest:

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Susan J. Hoover, MD, FACS

Latest:

Novel Radiotherapy Techniques Expand Options for Breast Cancer Patients

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

Susan Lutgendorf, PhD

Latest:

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

Susan M. O'Brien

Latest:

Dr. O'Brien Discusses Combination Venetoclax in CLL

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.

Susan M. O'Brien MD

Latest:

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Susan M. OBrien, MD The University of California, Irvine Medical Center

Susan Moore, RN, MSN

Latest:

Susan Moore on Oral Oncolytic Patient Education

Susan Moore on the Importance of Oral Oncolytic Patient Education

Susan Moran, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Susan N. Chi, MD

Latest:

Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative tumors.

Susan Oâ€™Brien, MD

Latest:

Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

Susan OÃ¢â‚¬â„¢Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Susan Peck, PhD

Latest:

Putting Key Developments in Two Tumor Types in Focus

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Susan R. Peck, PhD

Latest:

BATTLE-2: Next-Generation of Biomarker-Driven Trials

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center

Latest:

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Susan Sprague Yeske

Latest:

Oncology Nutritionists: Should cancer care teams include dietary experts?

Early screening and comprehensive assessment of risk for malnutrition is increasingly recognized as imperative in the development of standards of quality of care in oncology practices.

Susana Campos, MD, MPH

Latest:

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

Susana M. Campos, MD

Latest:

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.

Susana M. Campos, MD, MPH

Latest:

Key Takeaways and Closing Thoughts on ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Susanna Ulahannan, MD

Latest:

Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic Cancer

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.

Susanne Osanto, MD, PhD, Leiden University Medical Center

Suzanne A. W. Fuqua, PhD

Latest:

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.